Gufic Biosciences: Indore Plant Ramp-Up Sets the Stage for FY27 Recovery
​Specialty pharma company Gufic Biosciences closes FY26 with INR 940.5 crore revenue, focusing on Indore plant scale-up, export approvals, and...
Profit from India's Rapidly Growing Biotechnology Industry
Now is a strategic time to focus on the upside potential of biotechnology companies in India, as India’s biotechnology industry is projected to...
India's Budgets: 2006-2015. Key Charts, and Key questions
In continuation of my work of detailed work on India Budget for last ten years, this piece through simple charts puts in perspective: Â 2014 Actual...
Rubicon Research IPO - RHP Updates, Peer Comp and Thoughts on Valuation
Rubicon Research Limited (RR) is looking to raise about US$155m in its India IPO. In this note, we talk about the RHP updates, peer comp and...
No more insights